A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan, Martin Schuler, Yoon Koo Kang, Chia Jui Yen, Julien Edeline, Su Pin Choo, Chia Chi Lin, Takuji Okusaka, Karl Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean Frederic Blanc, Kyung Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong LimJordi Bruix, Andreas Geier, Carmen Guillén-Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea Myers, Jean Pierre Delord

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences